Naomi Schlesinger
( out of 24 reviews )

Naomi Schlesinger, MD

Languages spoken: Hebrew, English

Clinical Locations

Primary Location

University of Utah Hospital

Rheumatology, Area E
50 N Medical Dr
Salt Lake City , UT 84132
Get Directions

Dr. Naomi Schlesinger is a Harold J, Ardella T, and Helen T Stevenson Presidential Endowed Chair of Rheumatology, Professor and Chief Division of Rheumatology

Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT. She is a previous Chief of the Division of Rheumatology at Rutgers-Robert Wood Johnson Medical School and Director of Rutgers Robert Wood Johnson Medical School Gout Center. Dr. Schlesinger is a previous President of the NJ Rheumatology Association and current President of the Utah Rheumatology Association and was the recipient of the 2015 Rheumatologist of The Year award by the Arthritis Foundation - NJ Chapter.

Dr. Schlesinger is a noted authority in the field of gout, having published many papers regarding the diagnosis, treatment, and better understanding of the pathogenesis of gout. Dr. Schlesinger's research has won recognition, including the work titled: Efficacy of canakinumab (ACZ885), a fully human anti-Interleukin (IL)-1beta monoclonal antibody, in the prevention of flares in gout patients initiating allopurinol therapy, which was selected as one of the five highest-ranking abstracts that will likely shape our treatment paradigms for years to come in the 2010 ACR/ ARHP Annual Scientific Meeting and the work titled: Erectile dysfunction is common among gout patients, which was selected (one of 13) for inclusion in the official 2014 EULAR Press Conference from over 4000 abstracts. Other pioneering work includes the treatment of gout flares with topical ice, seasonality of gout, diagnosing gout using ultrasound, understanding the pathogenesis of bone erosions in gout, and the importance of anti-inflammatory treatment in gout.

Dr. Schlesinger serves as the American College of Rheumatology (ACR) abstract Co-Chair on metabolic and crystal arthropathies, a previous member of the ACR Global Engagement Special Committee (GESC), and a member of the ACR Annual Meeting Planning Committee (AMPC). She is a Co-Director of the International Gout and Hyperuricemia Center, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, and serves as a consultant to pharmaceutical companies in the field of gout.

Specialties

  • Gout

Board Certification

American Board of Internal Medicine (Sub: Rheumatology)

Patient Rating

4.9 /5
( out of 24 reviews )

The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

The scale on which responses are measured is 1 to 5 with 5 being the best score.

Patient Comments

Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

2025-08-22
UNIVERSITY HOSPITAL

Dr. Schlesinger is a caring professional. Great at listening to your concerns Great doctor.

2025-08-02
UNIVERSITY HOSPITAL

I would really like to share ,,But right now ,, I need her Knowledge ,,so I choose to say Im so grateful to say I'm her patient..

2025-07-02
UNIVERSITY HOSPITAL

I felt confident in her experience and education and her concern as an individual. She smiled a lot which relaxed me.

2025-06-20
UNIVERSITY HOSPITAL

Very good with my Gout treatment

2025-04-03
UNIVERSITY HOSPITAL

Dr Schlesinger is amazing, and is the best person to see if you have gout. She has so much experience and knowledge, and will spend the time it takes to help you get better.

2025-03-27
UNIVERSITY HOSPITAL

Dr. Schlesinger appears to be extremely knowledgeable about gout and other joint diseases. She also has a wonderful "bedside manner" and is very easy to understand and thorough. She is a good listener and asks good questions.

2025-02-14
UNIVERSITY HOSPITAL

Absolutely amazing person and Doctor. Listened to everything I have to say and answered all my questions. I very much appreciate her calling me personally to update on the results of my tests.

2024-12-12
UH HOSPITALS AND CLINICS

I waited several months to be able to see Dr. Schlesinger, but she was well worth the wait. She cared for me as a whole person, not just another interesting case of gout.

2024-10-31
UH HOSPITALS AND CLINICS

My experience with Dr. Schlesinger was outstanding. I found her to be very knowledgeable and very interested in helping me maintain the best health that I can. I'm happy to give her an unqualified recommendation.

Dr. Naomi Schlesinger is a Harold J, Ardella T, and Helen T Stevenson Presidential Endowed Chair of Rheumatology, Professor and Chief Division of Rheumatology

Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT. She is a previous Chief of the Division of Rheumatology at Rutgers-Robert Wood Johnson Medical School and Director of Rutgers Robert Wood Johnson Medical School Gout Center. Dr. Schlesinger is a previous President of the NJ Rheumatology Association and current President of the Utah Rheumatology Association and was the recipient of the 2015 Rheumatologist of The Year award by the Arthritis Foundation - NJ Chapter.

Dr. Schlesinger is a noted authority in the field of gout, having published many papers regarding the diagnosis, treatment, and better understanding of the pathogenesis of gout. Dr. Schlesinger's research has won recognition, including the work titled: Efficacy of canakinumab (ACZ885), a fully human anti-Interleukin (IL)-1beta monoclonal antibody, in the prevention of flares in gout patients initiating allopurinol therapy, which was selected as one of the five highest-ranking abstracts that will likely shape our treatment paradigms for years to come in the 2010 ACR/ ARHP Annual Scientific Meeting and the work titled: Erectile dysfunction is common among gout patients, which was selected (one of 13) for inclusion in the official 2014 EULAR Press Conference from over 4000 abstracts. Other pioneering work includes the treatment of gout flares with topical ice, seasonality of gout, diagnosing gout using ultrasound, understanding the pathogenesis of bone erosions in gout, and the importance of anti-inflammatory treatment in gout.

Dr. Schlesinger serves as the American College of Rheumatology (ACR) abstract Co-Chair on metabolic and crystal arthropathies, a previous member of the ACR Global Engagement Special Committee (GESC), and a member of the ACR Annual Meeting Planning Committee (AMPC). She is a Co-Director of the International Gout and Hyperuricemia Center, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, and serves as a consultant to pharmaceutical companies in the field of gout.

Board Certification and Academic Information

Academic Departments Internal Medicine -Professor
Academic Divisions Rheumatology
Board Certification
American Board of Internal Medicine (Sub: Rheumatology)

Education history

Professional Medical Medicine - Technion - Israel Institute of Technology M.D.
Internship Rotating - Technion - Israel Institute of Technology Intern
Internship Internal Medicine - Medical College of Pennsylvania Intern
Residency Internal Medicine - Jefferson Medical College of Thomas Jefferson University Resident
Fellowship Rheumatology - Medical College of Pennsylvania Fellow

Selected Publications

Journal Article

  1. Schlesinger N, Hoffman BI (1995). Fungal Bursitis: Olecranon Bursitis Caused by Candida parapsilosis with Review of the Literature. J Clin Rheumatol, 1(4), 232-5.
  2. Schlesinger N (1997). Identification of Gulf War syndrome: methodological issues and medical illnesses. JAMA, 278(5), 383; author reply 385-7.
  3. Schlesinger N, Gowin KM, Baker DG, Beutler AM, Hoffman BI, Schumacher HR Jr (1998). Acute gouty arthritis is seasonal. J Rheumatol, 25(2), 342-4.
  4. Schlesinger N, Schumacher HR Jr, Beutler AM (1998). Serum uric acid in acute gout. Ann Rheum Dis, 57(7), 443-4.
  5. Schlesinger N, Neustadter L, Schumacher HR (2000). Lytic Bone Lesions as a Prominent Feature in Waldenstrom's Macroglobulinemia. J Clin Rheumatol, 6(3), 150-3.
  6. Beutler AM, Rull M, Schlesinger N, Baker DG, Hoffman BI, Schumacher HR Jr (2001). Treatment with allopurinol decreases the number of acute gout attacks despite persistently elevated serum uric acid levels. Clin Exp Rheumatol, 19(5), 595.
  7. Schlesinger N, Detry MA, Holland BK, Baker DG, Beutler AM, Rull M, Hoffman BI, Schumacher HR Jr (2002). Local ice therapy during bouts of acute gouty arthritis. J Rheumatol, 29(2), 331-4.
  8. Schlesinger N, Katz M, Ingber A (2002). Nail involvement in pemphigus vulgaris. Br J Dermatol, 146(5), 836-9.
  9. Schlesinger N (2004). Clues to pathogenesis of fibromyalgia in patients with sickle cell disease. J Rheumatol, 31(3), 598-600.
  10. Schlesinger N, Lardizabal A, Rao J, Rao J, McDonald R (2005). Tuberculosis of the spine: experience in an inner city hospital. J Clin Rheumatol, 11(1), 17-20.
  11. Schlesinger N, Schlesinger M (2005). Seasonal variation of rheumatic diseases. Discov Med, 5(25), 64-9.
  12. Schlesinger N, Schlesinger M, Seshan SV (2005). Seasonal variation of lupus nephritis: high prevalence of class V lupus nephritis during the winter and spring. J Rheumatol, 32(6), 1053-7.
  13. Schumacher HR Jr, Edwards LN, Perez-Ruiz F, Becker M, Chen LX, Furst DE, Joseph-Ridge N, Schlesinger N, Horowitz Z, Saag K, Boice JA, Yamanaka H, OMERACT 7 Special Interest Group. (2005). Outcome measures for acute and chronic gout. J Rheumatol, 32(12), 2452-5.
  14. Schlesinger N, Moore DF, Sun JD, Schumacher HR Jr (2006). A survey of current evaluation and treatment of gout. J Rheumatol, 33(10), 2050-2.
  15. Schlesinger N (2006). Response to application of ice may help differentiate between gouty arthritis and other inflammatory arthritides. J Clin Rheumatol, 12(6), 275-6.
  16. Thiele RG, Schlesinger N (2007). Diagnosis of gout by ultrasound. Rheumatology (Oxford), 46(7), 1116-21.
  17. Petersel D, Schlesinger N (2007). Treatment of acute gout in hospitalized patients. J Rheumatol, 34(7), 1566-8.
  18. Schumacher HR, Taylor W, Joseph-Ridge N, Perez-Ruiz F, Chen LX, Schlesinger N, Khanna D, Furst DE, Becker MA, Dalbeth N, Edwards NL (2007). Outcome evaluations in gout. J Rheumatol, 34(6), 1381-5.
  19. Taylor WJ, Schumacher HR Jr, Baraf HS, Chapman P, Stamp L, Doherty M, McQueen F, Dalbeth N, Schlesinger N, Furst DE, Vazquez-Mellado J, Becker MA, Kavanaugh A, Louthrenoo W, Bardin T, Khanna D, Simon LS, Yamanaka H, Choi HK, Zeng X, Strand V, Grainger R, Clegg D, Singh JA, Diaz-Torne C, Boers M, Gow P, Barskova VG (2008). A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout. Ann Rheum Dis, 67(6), 888-91.
  20. Schlesinger N, Norquist JM, Watson DJ (2009). Serum urate during acute gout. J Rheumatol, 36(6), 1287-9.
  21. Grainger R, Taylor WJ, Dalbeth N, Perez-Ruiz F, Singh JA, Waltrip RW, Schlesinger N, Evans R, Edwards NL, Sivera F, Diaz-Torne C, MacDonald PA, McQueen FM, Schumacher HR (2009). Progress in measurement instruments for acute and chronic gout studies. J Rheumatol, 36(10), 2346-55.
  22. Schumacher HR, Taylor W, Edwards L, Grainger R, Schlesinger N, Dalbeth N, Sivera F, Singh J, Evans R, Waltrip RW, Diaz-Torne C, MacDonald P, McQueen F, Perez-Ruiz F (2009). Outcome domains for studies of acute and chronic gout. J Rheumatol, 36(10), 2342-5.
  23. Schlesinger N, Hassett AL, Neustadter L, Schumacher HR Jr (2009). Does acute synovitis (pseudogout) occur in patients with chronic pyrophosphate arthropathy (pseudo-osteoarthritis)? Clin Exp Rheumatol, 27(6), 940-4.
  24. Thiele RG, Schlesinger N (2010). Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved. Rheumatol Int, 30(4), 495-503.
  25. So A, De Meulemeester M, Pikhlak A, Yücel AE, Richard D, Murphy V, Arulmani U, Sallstig P, Schlesinger N (2010). Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum, 62(10), 3064-76.
  26. Schlesinger N, Thiele RG (2010). The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis, 69(11), 1907-12.
  27. Schlesinger N, Yasothan U, Kirkpatrick P (2011). Pegloticase. Nat Rev Drug Discov, 10(1), 17-8.
  28. Schlesinger N, De Meulemeester M, Pikhlak A, Yücel AE, Richard D, Murphy V, Arulmani U, Sallstig P, So A (2011). Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther, 13(2), R53.
  29. Schlesinger N, Mysler E, Lin HY, De Meulemeester M, Rovensky J, Arulmani U, Balfour A, Krammer G, Sallstig P, So A (2011). Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis, 70(7), 1264-71.
  30. Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, Krammer G, Murphy V, Richard D, So AK (2012). Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis, 71(11), 1839-48.
  31. Singh JA, Taylor WJ, Dalbeth N, Simon LS, Sundy J, Grainger R, Alten R, March L, Strand V, Wells G, Khanna D, McQueen F, Schlesinger N, Boonen A, Boers M, Saag KG, Schumacher HR, Edwards NL (2014). OMERACT endorsement of measures of outcome for studies of acute gout. J Rheumatol, 41(3), 569-73.
  32. Hsu V, Bramwit M, Schlesinger N (2015). Dual-energy computed tomography for the evaluation of calcinosis in systemic sclerosis. J Rheumatol, 42(2), 345-6.
  33. Schlesinger N, Radvanski DC, Young TC, McCoy JV, Eisenstein R, Moore DF (2015). Diagnosis and Treatment of Acute Gout at a University Hospital Emergency Department. Open Rheumatol J, 9, 21-6.
  34. Pinals RS, Schlesinger N (2015). Did Michelangelo Have Gout? J Clin Rheumatol, 21(7), 364-7.
  35. Vargas-Santos AB, Castelar-Pinheiro Gda R, Coutinho ES, Schumacher HR Jr, Singh JA, Schlesinger N (2015). Adherence to the 2012 American College of Rheumatology (ACR) Guidelines for Management of Gout: A Survey of Brazilian Rheumatologists. PLoS One, 10(8), e0135805.
  36. Schlesinger N, Radvanski DC, Cheng JQ, Kostis JB (2015). Erectile Dysfunction Is Common among Patients with Gout. J Rheumatol, 42(10), 1893-7.
  37. Hsu V, Bramwit M, Schlesinger N (2015). Use of dual-energy computed tomography for the evaluation of calcinosis in patients with systemic sclerosis. Clin Rheumatol, 34(9), 1557-61.
  38. Schlesinger N, Etzel CJ, Greenberg J, Kremer J, Harrold LR (2016). Gout Prophylaxis Evaluated According to the 2012 American College of Rheumatology Guidelines: Analysis from the CORRONA Gout Registry. J Rheumatol, 43(5), 924-30.
  39. de Lautour H, Taylor WJ, Adebajo A, Alten R, Burgos-Vargas R, Chapman P, Cimmino MA, da Rocha Castelar Pinheiro G, Day R, Harrold LR, Helliwell P, Janssen M, Kerr G, Kavanaugh A, Khanna D, Khanna PP, Lin C, Louthrenoo W, McCarthy G, Vazquez-Mellado J, Mikuls TR, Neogi T, Ogdie A, Perez-Ruiz F, Schlesinger N, Ralph Schumacher H, Scirè CA, Singh JA, Sivera F, Slot O, Stamp LK, Tausche AK, Terkeltaub R, Uhlig T, van de Laar M, White D, Yamanaka H, Zeng X, Dalbeth N (2016). Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. Arthritis Care Res (Hoboken), 68(5), 667-72.
  40. Pierre K, Schlesinger N, Androulakis IP (2016). The role of the hypothalamic-pituitary-adrenal axis in modulating seasonal changes in immunity. Physiol Genomics, 48(10), 719-738.
  41. Rao RT, Pierre KK, Schlesinger N, Androulakis IP (2016). The Potential of Circadian Realignment in Rheumatoid Arthritis. Crit Rev Biomed Eng, 44(3), 177-191.
  42. Harrold LR, Etzel CJ, Gibofsky A, Kremer JM, Pillinger MH, Saag KG, Schlesinger N, Terkeltaub R, Cox V, Greenberg JD (2017). Sex differences in gout characteristics: tailoring care for women and men. BMC Musculoskelet Disord, 18(1), 108.
  43. Hsu VM, Emge T, Schlesinger N (2017). X-ray diffraction analysis of spontaneously draining calcinosis in scleroderma patients. Scand J Rheumatol, 46(2), 118-121.
  44. Aqel SI, Hampton JM, Bruss M, Jones KT, Valiente GR, Wu LC, Young MC, Willis WL, Ardoin S, Agarwal S, Bolon B, Powell N, Sheridan J, Schlesinger N, Jarjour WN, Young NA (2017). Daily Moderate Exercise Is Beneficial and Social Stress Is Detrimental to Disease Pathology in Murine Lupus Nephritis. Front Physiol, 8, 236.
  45. Pierre K, Schlesinger N, Androulakis IP (2017). The Hepato-Hypothalamic-Pituitary-Adrenal-Renal Axis: Mathematical Modeling of Cortisol's Production, Metabolism, and Seasonal Variation. J Biol Rhythms, 32(5), 469-484.
  46. Bursill D, Taylor WJ, Terkeltaub R, Kuwabara M, Merriman TR, Grainger R, Pineda C, Louthrenoo W, Edwards NL, Andrés M, Vargas-Santos AB, Roddy E, Pascart T, Lin CT, Perez-Ruiz F, Tedeschi SK, Kim SC, Harrold LR, McCarthy G, Kumar N, Chapman PT, Tausche AK, Vazquez-Mellado J, Gutierrez M, da Rocha Castelar-Pinheiro G, Richette P, Pascual E, Fisher MC, Burgos-Vargas R, Robinson PC, Singh JA, Jansen TL, Saag KG, Slot O, Uhlig T, Solomon DH, Keenan RT, Scire CA, Biernat-Kaluza E, Dehlin M, Nuki G, Schlesinger N, Janssen M, Stamp LK, Sivera F, Reginato AM, Jacobsson L, Lioté F, Ea HK, Rosenthal A, Bardin T, Choi HK, Hershfield MS, Czegley C, Choi SJ, Dalbeth N (2019). Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. Arthritis Care Res (Hoboken), 71(3), 427-434.
  47. Bursill D, Taylor WJ, Terkeltaub R, Abhishek A, So AK, Vargas-Santos AB, Gaffo AL, Rosenthal A, Tausche AK, Reginato A, Manger B, Sciré C, Pineda C, van Durme C, Lin CT, Yin C, Albert DA, Biernat-Kaluza E, Roddy E, Pascual E, Becce F, Perez-Ruiz F, Sivera F, Lioté F, Schett G, Nuki G, Filippou G, McCarthy G, da Rocha Castelar Pinheiro G, Ea HK, Tupinambá HA, Yamanaka H, Choi HK, Mackay J, ODell JR, Vázquez Mellado J, Singh JA, Fitzgerald JD, Jacobsson LTH, Joosten L, Harrold LR, Stamp L, Andrés M, Gutierrez M, Kuwabara M, Dehlin M, Janssen M, Doherty M, Hershfield MS, Pillinger M, Edwards NL, Schlesinger N, Kumar N, Slot O, Ottaviani S, Richette P, MacMullan PA, Chapman PT, Lipsky PE, Robinson P, Khanna PP, Gancheva RN, Grainger R, Johnson RJ, Te Kampe R, Keenan RT, Tedeschi SK, Kim S, Choi SJ, Fields TR, Bardin T, Uhlig T, Jansen T, Merriman T, Pascart T, Neogi T, Klück V, Louthrenoo W, Dalbeth N (2019). Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Ann Rheum Dis, 78(11), 1592-1600.
  48. Schlesinger N, Edwards NL, Khanna PP, Yeo AE, Lipsky PE (2019). Evaluation of Proposed Criteria for Remission and Evidence-Based Development of Criteria for Complete Response in Patients With Chronic Refractory Gout. ACR Open Rheumatol, 1(4), 236-243.
  49. Edwards NL, Schlesinger N, Clark S, Arndt T, Lipsky PE (2020). Management of Gout in the United States: A Claims-based Analysis. ACR Open Rheumatol, 2(3), 180-187.
  50. Schlesinger N, Edwards NL, Yeo AE, Lipsky PE (2020). Development of a multivariable improvement measure for gout. Arthritis Res Ther, 22(1), 164.
  51. Schlesinger N, Firestein BL, Brunetti L (2020). Colchicine in COVID-19: an Old Drug, New Use. Curr Pharmacol Rep, 6(4), 137-145.
  52. Brunetti L, Diawara O, Tsai A, Firestein BL, Nahass RG, Poiani G, Schlesinger N (2020). Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19. J Clin Med, 9(9).
  53. Huang YF, Yang KH, Chen SH, Xie Y, Huang CB, Qing YF, He DY, Wu LJ, Zhan F, Wang XQ, Zhou YQ, Kong QC, Wang K, Schlesinger N, Xu DT, Ma XJ, Gu JR (2020). [Practice guideline for patients with hyperuricemia/gout]. Zhonghua Nei Ke Za Zhi, 59(7), 519-527.
  54. Jablonski K, Young NA, Henry C, Caution K, Kalyanasundaram A, Okafor I, Harb P, Schwarz E, Consiglio P, Cirimotich CM, Bratasz A, Sarkar A, Amer AO, Jarjour WN, Schlesinger N (2020). Physical activity prevents acute inflammation in a gout model by downregulation of TLR2 on circulating neutrophils as well as inhibition of serum CXCL1 and is associated with decreased pain and inflammation in gout patients. PLoS One, 15(10), e0237520.
  55. Fan M, Liu J, Zhao B, Wu X, Li X, Gu J, Schlesinger N (2021). Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials. Clin Rheumatol, 40(2), 683-692.
  56. Hsu VM, Kozák E, Li Q, Bocskai M, Schlesinger N, Rosenthal A, McClure ST, Kovács L, Bálint L, Szamosi S, Szücs G, Carns M, Aren K, Goldberg I, Váradi A, Varga J (2022). Inorganic pyrophosphate is reduced in patients with systemic sclerosis. Rheumatology (Oxford), 61(3), 1158-1165.
  57. Schlesinger N, Elsaid MI, Rustgi VK (2022). The relationship between metabolic syndrome severity and the risk of mortality in gout patients: a population-based study. Clin Exp Rheumatol, 40(3), 631-633.
  58. Schlesinger N, Rustgi VK, Yeo AE, Lipsky PE (2022). Improvement in hepatic fibrosis estimated by Fibrosis-4 index in pegloticase treated chronic refractory gout patients.(Epub ahead of print). Clin Exp Rheumatol.
  59. Brunetti L, Vekaria J, Lipsky PE, Schlesinger N (2022). Treatment of Acute Gout Flares in the Emergency Department: Prescribing Patterns and Revisit Rates. Ann Pharmacother, 56(4), 422-429.
  60. Schlesinger N, Sloan VS, Panush RS (2022). Numb From Rejection: Academic Publishing Is Not for the Faint-hearted. J Rheumatol, 49(5), 540-541.
  61. Schlesinger N, Lipsky PE, Jablonski K, Jarjour W, Brunetti L, Young NA (2022). Components of tart cherry juice inhibit NF'B activation and inflammation in acute gout. Clin Exp Rheumatol, 40(7), 1293-1298.
  62. Schlesinger N, Baker DG, Schumacher HR Jr (2000). Gout: How well have diagnostic tests and therapies been evaluated? Curr Opin Orthop, 11, 71-6.
  63. Schlesinger N (2006). Reply: Seasonal variation of primary neuropsychiatric SLE. J Rheumatol, 33(9), 1914.
  64. Perez-Ruiz F, Dalbeth N, Schlesinger N (2008). Febuxostat, a novel drug for the treatment of hyperuricemia and gout. Future Medicine, 3(5), 421-7.
  65. Kimel AF, Schlesinger N (2009). Polymyalgia Rheumatica: to unmask the real culprit. J Clin Outcomes Manag, 16(3), 137-45.
  66. Edwards NL, Schlesinger N (2009). Gout: scale of the disease. Clin Geriatr, 9(Suppl 4).
  67. Schlesinger N (2009). Management of gout in seniors: addressing barriers and setting goals for optimal control. Clin Geriatr, 9(Suppl 4), 8-14.
  68. Schlesinger N, Rabinowitz R, Schlesinger M (2012). Pilot Studies of Cherry Juice Concentrate for Gout Flare Prophylaxis. J Arthritis, 1, 1.
  69. Schlesinger N, Maniatis G, Sharma R, Veysman BD (2012). The Diagnostic Eclipse. Hektoen Int, 4(2).
  70. Pai S, Schlesinger N (2014). Some safety concerns when using drugs for acute and chronic gout. Drug Safety Quarterly, Summer(5), 1-4.
  71. Pai S, Raslan A, Schlesinger N (2015). Gout: Update on current therapeutics. Curr Treatm Opt Rheumatol, 1, 131-42.
  72. Schlesinger N (2015). Diagnosis of Gout: A Review to Aid the Clinician. Gout and Hyperuricemia, 2(4), 118-20.
  73. Schlesinger N (2016). Reply: Lv ZT, Chen A. Vitamin D deficiency may explain the possible link between gout and erectile dysfunction. J Rheumatol, 43(8), 1617.
  74. Schlesinger N (2016). Gout Prophylaxis Evaluated According to the 2012 American College of Rheumatology Guidelines: Analysis from the CORRONA Gout Registry. Clinical Highlights for the Rheumatologist, 5(3), 38.
  75. Schlesinger N, Lu N, Choi HK (2018). Incident Gout and the Risk of Incident Erectile Dysfunction: A BMI-Matched Population-Based Study. J Rheumatol, 45(8), 1192-7.
  76. Schlesinger N, Alikhan M, Doty RL (2019). Is the Sense of Smell Impaired in Gout Patients? Annals of Arthritis and Clinical Rheumatology, 2(1), 1008.
  77. Abdel Megid M, Borham A, Schlesinger N (2019). A case of dermatomyositis in a patient with Merkel Cell Carcinoma. Annals of Arthritis and Clinical Rheumatology, 2(1), 1009.
  78. Talaat M, Park K, Schlesinger N (2021). Contentious issues in gout management: the story so far. Open Access Rheumatol, 13, 111-22.
  79. Park K, Gupta NK, Olweny EO, Schlesinger N (2021). Beyond Arthritis: Understanding the Influence of Gout on Erectile Function: A Systematic Review. Urology, 153, 19-27.
  80. McKenzie BJ, Wechalekar MD, Johnston RV, Schlesinger N, Buchbinder R. (2021). Colchicine for acute gout. Cochrane Database Syst Rev, 26(8).
  81. Kaveney A, Philipp CS, Prendergast NC, Kane I, Schlesinger N (2021). Muscular hematomas and COVID 19: A missed diagnosis? Annals of Short Reports and Clinical Images, 3(1), 1024.
  82. Schlesinger N (2006). What next when gout remains afoot? Consultant, 46, 144.
  83. Kaufmann D, Chaiyakunapruk N, Schlesinger (2024). Optimizing Gout Treatment: A Comprehensive Review of Current and Emerging Uricosurics. Joint bone spine, 105826.
  84. Brikman S, Serfaty L, Abuhasira R, Schlesinger N, Bieber A, Rappoport (2024). A machine learning-based prediction model for gout in hyperuricemics: a nationwide cohort study. Rheumatology (Oxford, England), 63(9), 2411-2417.
  85. Schlesinger N, Patel A, Rustgi VK, Yeo AE, Lipsky P (2024). Increased frequency of hepatic steatosis and fibrosis in patients with gout detected by transient elastography. Clinical and experimental rheumatology, 42(1), 86-91.
  86. Schlesinger N, Pillinger MH, Lipsky P (2024). Knowledge of and Stated Adherence to the 2020 ACR Guideline for Gout Management: Results of a Survey of US Rheumatologists. The Journal of rheumatology,
  87. Ramessar N, Borad A, Schlesinger (2023). The impact of curcumin supplementation on systemic lupus erythematosus and lupus nephritis: A systematic review. Lupus, 32(5), 644-657.
  88. Sathapanasiri T, Meraz M, Mokri H, K Veettil S, Wijarnpreecha K, Schlesinger N, Kavanaugh A, Chaiyakunapruk (2025). Gastrointestinal Perforation as a Safety Concern Among Patients With Rheumatoid Arthritis Receiving JAK Inhibitor Therapy: A Systematic Review and Network Meta-Analysis. Arthritis care & research, 77(10), 1222-1228.
  89. Schlesinger N, Rosenstein ED, Panush R (2025). A Dromedary Tale: A Tragi-Comedary on Science, Where Reliance Over Defiance Must Prevail. The Journal of rheumatology, 52(8), 839.
  90. Brikman S, Perets O, Serfaty L, Abuhasira R, Schlesinger N, Ayalon S, Bieber A, Rappoport (2025). Incidence of gout diagnosis among participants with hyperuricemia, insights from a nationwide cohort study. Seminars in arthritis and rheumatism, 74, 152764.
  91. Schlesinger N, Androulakis I (2025). Seasonal Variation in Public Interest in Gout: Longitudinal Infodemiology Study Using Google Trends (2014-2024). Journal of medical Internet research, 27, e75415.
  92. Maldonado-Catala P, Gouripeddi R, Schlesinger N, Facelli J (2025). Molecular Mimicry Impact of the COVID-19 Pandemic: Sequence Homology Between SARS-CoV-2 and Autoimmune Diseases Epitopes. Immunoinformatics (Amsterdam, Netherlands), 18,
  93. Deshpande K, Lange KR, Stone WB, Yohn C, Schlesinger N, Kagan L, Auguste AJ, Firestein BL, Brunetti (2023). The influence of SARS-CoV-2 infection on expression of drug-metabolizing enzymes and transporters in a hACE2 murine model. Pharmacology research & perspectives, 11(3), e01071.
  94. Brunetti L, Wang L, Wassef A, Gong Y, Brinker A, Buckley B, Lipsky PE, Ondar P, Poiani G, Zhao L, Kong AN, Schlesinger (2023). Pharmacokinetics and Pharmacodynamics of Anthocyanins after Administration of Tart Cherry Juice to Individuals with Gout. Molecular nutrition & food research, 67(9), e2200550.
  95. Schlesinger N, Panush R (2023). Unexpected Moments in Telemedicine. The Journal of rheumatology, 50(2), 285-286.
  96. Schlesinger N, Lu N, Choi H (2018). Gout and the Risk of Incident Erectile Dysfunction: A Body Mass Index-matched Population-based Study. The Journal of rheumatology, 45(8), 1192-1197.
  97. Schlesinger N, Hoffman B (1997). Bursitis in acute bacterial endocarditis. Journal of clinical rheumatology, 3(2), 119.

Review

  1. Schlesinger N, Baker DG, Schumacher HR Jr (1999). How well have diagnostic tests and therapies for gout been evaluated? [Review]. Curr Opin Rheumatol, 11, (5), 441-5.
  2. Schlesinger N, Schumacher HR Jr (2001). Gout: can management be improved? [Review]. Curr Opin Rheumatol, 13, (3), 240-4.
  3. Schlesinger N, Schumacher HR Jr (2002). Update on gout. [Review]. Arthritis Rheum, 47, (5), 563-5.
  4. Schlesinger N (2004). Management of acute and chronic gouty arthritis: present state-of-the-art. [Review]. Drugs, 64, (21), 2399-416.
  5. Schlesinger N (2005). Dietary factors and hyperuricaemia. [Review]. Curr Pharm Des, 11, (32), 4133-8.
  6. Schlesinger N (2005). Diagnosis of gout: clinical, laboratory, and radiologic findings. [Review]. Am J Manag Care, 11, (15 Suppl), S443-50; quiz S465-8.
  7. Schlesinger N, Schumacher R, Catton M, Maxwell L (2006). Colchicine for acute gout. [Review]. Cochrane Database Syst Rev, (4), CD006190.
  8. Schlesinger N (2007). Reassessing the safety of intravenous and compounded injectable colchicine in acute gout treatment. [Review]. Expert Opin Drug Saf, 6, (6), 625-9.
  9. Schlesinger N (2007). Diagnosis of gout. [Review]. Minerva Med, 98, (6), 759-67.
  10. Perez-Ruiz F, Schlesinger N (2008). Management of gout. [Review]. Scand J Rheumatol, 37, (2), 81-9.
  11. Schlesinger N (2008). Overview of the management of acute gout and the role of adrenocorticotropic hormone. [Review]. Drugs, 68, (4), 407-15.
  12. Ebert EC, Hagspiel KD, Nagar M, Schlesinger N (2008). Gastrointestinal involvement in polyarteritis nodosa. [Review]. Clin Gastroenterol Hepatol, 6, (9), 960-6.
  13. Schlesinger I, Schlesinger N (2008). Uric acid in Parkinson's disease. [Review]. Mov Disord, 23, (12), 1653-7.
  14. Perez-Ruiz F, Dalbeth N, Urresola A, de Miguel E, Schlesinger N (2009). Imaging of gout: findings and utility. [Review]. Arthritis Res Ther, 11, (3), 232.
  15. Schlesinger N, Dalbeth N, Perez-Ruiz F (2009). Gout--what are the treatment options? [Review]. Expert Opin Pharmacother, 10, (8), 1319-28.
  16. Schlesinger N (2010). Diagnosing and treating gout: a review to aid primary care physicians. [Review]. Postgrad Med, 122, (2), 157-61.
  17. Schlesinger N (2010). New agents for the treatment of gout and hyperuricemia: febuxostat, puricase, and beyond. [Review]. Curr Rheumatol Rep, 12, (2), 130-4.
  18. Schlesinger N (2011). Difficult-to-treat gouty arthritis: a disease warranting better management. [Review]. Drugs, 71, (11), 1413-39.
  19. Schlesinger N (2012). Canakinumab in gout. [Review]. Expert Opin Biol Ther, 12, (9), 1265-75.
  20. Schlesinger N (2012). Treatment of chronic gouty arthritis: it is not just about urate-lowering therapy. [Review]. Semin Arthritis Rheum, 42, (2), 155-65.
  21. Wechalekar MD, Vinik O, Schlesinger N, Buchbinder R (2013). Intra-articular glucocorticoids for acute gout. [Review]. Cochrane Database Syst Rev, (4), CD009920.
  22. Schlesinger N (2014). Anti-interleukin-1 therapy in the management of gout. [Review]. Curr Rheumatol Rep, 16, (2), 398.
  23. Schlesinger N (2014). Treatment of acute gout. [Review]. Rheum Dis Clin North Am, 40, (2), 329-41.
  24. van Echteld I, Wechalekar MD, Schlesinger N, Buchbinder R, Aletaha D (2014). Colchicine for acute gout. [Review]. Cochrane Database Syst Rev, (8), CD006190.
  25. van Durme CM, Wechalekar MD, Buchbinder R, Schlesinger N, van der Heijde D, Landewé RB (2014). Non-steroidal anti-inflammatory drugs for acute gout. [Review]. Cochrane Database Syst Rev, (9), CD010120.
  26. Keenan RT, Schlesinger N (2016). New and Pipeline Drugs for Gout. [Review]. Curr Rheumatol Rep, 18, (6), 32.
  27. Sharon Y, Schlesinger N (2016). Beyond Joints: a Review of Ocular Abnormalities in Gout and Hyperuricemia. [Review]. Curr Rheumatol Rep, 18, (6), 37.
  28. Schlesinger N (2017). The safety of treatment options available for gout. [Review]. Expert Opin Drug Saf, 16, (4), 429-436.
  29. Bieber A, Schlesinger N, Fawaz A, Mader R (2018). Chronic tophaceous gout as the first manifestation of gout in two cases and a review of the literature. [Review]. Semin Arthritis Rheum, 47, (6), 843-848.
  30. Hsu V, Varga J, Schlesinger N (2019). Calcinosis in scleroderma made crystal clear. [Review]. Curr Opin Rheumatol, 31, (6), 589-594.
  31. Scherholz ML, Schlesinger N, Androulakis IP (2019). Chronopharmacology of glucocorticoids. [Review]. Adv Drug Deliv Rev, 151-152, 245-261.
  32. Schlesinger N, Brunetti L (2020). Beyond urate lowering: Analgesic and anti-inflammatory properties of allopurinol. [Review]. Semin Arthritis Rheum, 50, (3), 444-450.
  33. Schlesinger N, Lipsky PE (2020). Pegloticase treatment of chronic refractory gout: Update on efficacy and safety. [Review]. Semin Arthritis Rheum, 50, (3S), S31-S38.
  34. Bodofsky S, Merriman TR, Thomas TJ, Schlesinger N (2020). Advances in our understanding of gout as an auto-inflammatory disease. [Review]. Semin Arthritis Rheum, 50, (5), 1089-1100.
  35. Carcione J, Bodofsky S, LaMoreaux B, Schlesinger N (2020). Beyond Medical Treatment: Surgical Treatment of Gout. [Review]. Curr Rheumatol Rep, 23, (1), 1.
  36. Talaat M, Park K, Schlesinger N (2021). Contentious Issues in Gout Management: The Story so Far. [Review]. Open Access Rheumatol, 13, 111-122.
  37. Park K, Gupta NK, Olweny EO, Schlesinger N (2021). Beyond Arthritis: Understanding the Influence of Gout on Erectile Function: A Systematic Review. [Review]. Urology, 153, 19-27.
  38. McKenzie BJ, Wechalekar MD, Johnston RV, Schlesinger N, Buchbinder R (2021). Colchicine for acute gout. [Review]. Cochrane Database Syst Rev, 8, CD006190.
  39. Ramessar N, Borad A, Schlesinger N (2022). The effect of Omega-3 fatty acid supplementation in systemic lupus erythematosus patients: A systematic review. [Review]. Lupus, 31, (3), 287-296.
  40. Schlesinger N, Padnick-Silver L, LaMoreaux B (2022). Enhancing the Response Rate to Recombinant Uricases in Patients with Gout. [Review]. BioDrugs, 36, (2), 95-103.
  41. Schlesinger N, Brunetti L, Androulakis IP (2022). Does seasonality of the microbiota contribute to the seasonality of acute gout flare? [Review]. Clin Exp Rheumatol.
  42. Johnson RJ, Mandell BF, Schlesinger N, Mount DB, Botson JK, Abdellatif AA, Rhoades R, Singh J (2024). Controversies and practical management of patients with gout and chronic kidney disease. Kidney international, 106(4), 573-582.
  43. Schlesinger N, Pérez-Ruiz F, Lioté (2023). Mechanisms and rationale for uricase use in patients with gout. Nature reviews. Rheumatology, 19(10), 640-649.
  44. Schlesinger N, Pillinger MH, Simon LS, Lipsky P (2023). Interleukin-1ß inhibitors for the management of acute gout flares: a systematic literature review. Arthritis research & therapy, 25(1), 128.
  45. Schlesinger N, Kaufmann (2025). Updates in uricase therapy for gout. Current opinion in rheumatology, 37(6), 422-429.
  46. Kaufmann D, Schlesinger (2025). Could Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists Play a Role in Gout Treatment?. Pharmaceutics, 17(7),

Book

  1. Dalbeth N, Perez-Ruiz F, Schlesinger N (2012). Gout. Future Science Group E-Book Series.
  2. Schlesinger N, Lipsky P (2018). Gout (1st Edition). Elsevier.

Book Chapter

  1. Schlesinger N (1999). Connective tissue disorders. In Singleton JK, Sandowski SA, Green-Hernandez C, Hovath TV, DiGregorio RV, Holzemer SP (Eds.), Primary Care (pp. 32-452). Lippincott-Raven.
  2. Schlesinger N (2001). Osteoarthritis: pathology, epidemiology and risk factors. In Stitik TP (Ed.), Osteoarthritis [Physical Medicine and Rehabilitation: State of the Art Reviews] (15: 1, pp. 1-9). Philadelphia: Hanley and Belfus Publishers.
  3. Schlesinger N, Schumacher HR (2003). Gout: How much of what we do is evidence based? In Tugwell P, Shea B (Eds.), Evidence-based Rheumatology (pp. 65-95). London: British Medical Journal Books.
  4. Schlesinger N (2007). Chapter 187: Gout. In Buttaro TM, Trybulski J, Bailey PP, Sandberg-Cook J (Eds.), Primary Care: A Collaborative Practice (3rd Edition, pp. 952-7). Elsevier Publishers.
  5. Schlesinger N (2008). Chapter 10: Hyperuricemia, Gout and Diet. In Coleman LA (Ed.), Nutrition and Rheumatic Disease (pp. 169-82). Humana Press, Inc.
  6. Schlesinger N (2012). Chapter 175: Gout. In Trybulski J, Bailey PP, Sandberg-Cook J (Eds.), Primary Care: A Collaborative Practice (4th Edition, pp. 916-20). Elsevier.
  7. Schlesinger N (2012). Chapter 10: Treatment of Acute Gout. In Terkeltaub R (Ed.), Gout and Crystal-Induced Arthropathies (1st Edition, pp. 121-30). Elsevier.
  8. Dalbeth N, Perez-Ruiz F, Schlesinger N. (2013). Gout. In Dalbeth N, Perez-Ruiz F, Schlesinger N (Eds.), Future Science Group (FSG) E-Book Series (pp. 2-5).
  9. Schlesinger N (2013). Chapter 5: Clinical Features of Gout. In Dalbeth N, Perez-Ruiz F, Schlesinger N (Eds.), Future Science Group (FSG) E-Book Series (pp. 70-7).
  10. Schlesinger N (2013). Chapter 16: Therapies for Acute Flares and Gout Flare Prophylaxis. In Dalbeth N, Perez-Ruiz F, Schlesinger N (Eds.), E-book Series: Gout (pp. 202-211). Future Science Group.
  11. Keenan R, Pai S, Schlesinger N (2016). Chapter 43: Imaging of gout. In Doherty M, Arden N, Hunter D, Bijlsma H, Dalbeth N (Eds.), Oxford Textbook of Osteoarthritis and Crystal Arthropathy (Oxford Textbooks in Rheumatology) (3rd Edition). Oxford University Press.
  12. Schlesinger N (2017). Chapter 176: Gout. In Buttaro TM, Trybulski J, Bailey PP, Sandberg-Cook J (Eds.), Primary Care: A Collaborative Practice (5th Edition, pp. 928-32). Elsevier.
  13. Schlesinger N (2018). Section 17. Crystal-Related Arthropathies Rheumatology, Chapter 191: Clinical Features of Gout. In Silman AJ, Hochberg MC, Smolen JS, Weinblatt ME, Weisman MH (Eds.), Rheumatology, 2-Volume Set (7th Edition). Elsevier.
  14. Schlesinger N, Lipsky PE (2018). Preface. In Schlesinger N, Lipsky EP (Eds.), Gout (1st Edition). Elsevier.
  15. Schlesinger N (2018). Chapter 13: Nonpharmacologic treatment of gout. In Schlesinger N, Lipsky EP (Eds.), Gout (1st Edition). Elsevier.
  16. Schlesinger N (2018). Chapter 15: Current Pharmacological Treatments of Chronic Gout. In Schlesinger N, Lipsky EP (Eds.), Gout (1st Edition). Elsevier.
  17. Schlesinger N (2018). Current Pharmacological Treatments of Chronic Gout. In Schlesinger N, Lipsky EP (Eds.), Gout (1st Edition). Elsevier.
  18. Schlesinger N (2018). Epilogue. In Schlesinger N, Lipsky EP (Eds.), Gout (1st Edition). Elsevier.
  19. Schlesinger N, Kay JC (2019). Chapter 34: Gouty Inflammation. In Hashkes P, Laxer R, Simon A (Eds.), Textbook of Autoinflammation (1st Edition, pp. 635-45). Springer.
  20. Schlesinger N (2020). Chapter 158: Gout. In Buttaro TM, Trybulski J, Bailey PP, Sandberg-Cook J (Eds.), Primary Care: A Collaborative Practice (6th Edition). Elsevier.
  21. Schlesinger N (2022). Clinical Features of Gout. In Stone JH (Ed.), A Clinician's Pearls and Myths in Rheumatology (Second Edition). Springer.
  22. Schlesinger N (2022). Gout Treatment. In Stone JH (Ed.), A Clinician's Pearls and Myths in Rheumatology (Second Edition). Springer.
  23. Schlesinger N (2022). Chapter 160: Gout. In Buttaro TM, Trybulski J, Bailey PP, Sandberg-Cook J (Eds.), Primary Care: A Collaborative Practice (7th Edition). Elsevier.
  24. Schlesinger N (2022). Section Crystal-Related Arthropathies, Chapter 194: Clinical Features of Gout. In Silman AJ, Hochberg MC, Smolen JS, Weinblatt ME, Weisman MH (Eds.), Rheumatology, 2-Volume Set (8th Edition). Elsevier.
  25. Schlesinger (2024). Gout. 1049¿1053.

Commentary

  1. Schlesinger N (2004). Purine-rich foods and the risk of gout in men. N Engl J Med, 350(24), 2520-1; author reply 2520-1.
  2. Schlesinger I, Schlesinger N (2008). Re: Gout and risk of Parkinson disease: a prospective study. Neurology, 71(1), 70; author reply 70.
  3. Dalbeth N, Perez-Ruiz F, Edwards NL, Schlesinger N (2008). In defense of research into the crystal induced arthropathies. J Rheumatol, 35(11), 2278-9; author reply 2279.
  4. Schlesinger N (2008). Febuxostat : a viewpoint by Naomi Schlesinger. Drugs, 68(13), 1875-6.

Case Report

  1. Lam A, Toma W, Schlesinger N (2006). Mycobacterium marinum arthritis mimicking rheumatoid arthritis. J Rheumatol, 33(4), 817-9.
  2. Chehab MR, Goyal J, Schlesinger N (2012). Tophaceous pustule-like rash in a patient with gout. J Rheumatol, 39(1), 194-5.
  3. Sedhom D, Herrmann A, D'Souza M, Fyfe B, Zaldana F, Schlesinger N, Rustgi V (2018). Vanishing Bile Duct Syndrome in a Patient with Uterine Cancer and Paraneoplastic Systemic Sclerosis. ACG Case Rep J, 5 e95.
  4. Schlesinger N, Kapila R (2000). Tendinitis during the course of an acute hepatitis B virus infection. J Clin Rheumatol, 6(2), 10.

Editorial

  1. Schlesinger N (2011). Can ultrasonography make identification of asymptomatic hyperuricemic individuals at risk for developing gouty arthritis more crystal clear? Arthritis Res Ther, 13(2), 107.
  2. Schlesinger N (2016). Crystal arthritis: New recommendations highlight the need for more research. Nat Rev Rheumatol, 12(11), 628-630.
  3. Schlesinger N (2011). The role of ultrasonography in imaging of gouty arthritis. Imaging in Medicine, 3(6), 609-11.
  4. Schlesinger N, Drummond M, Abdul-Sater (2025). Of Mice and Men: Gout and Exercise. International journal of rheumatic diseases, 28(2), e70135.

Letter

  1. Schlesinger N, Huppert A, Hoch S (1995). Cyclosporine and methotrexate for severe rheumatoid arthritis. [Letter to the editor]. N Engl J Med, 333(23), 1567; author reply 1568-9.
  2. Schlesinger N, Baker DG, Schumacher HR Jr (1997). Persian Gulf War myalgia syndrome. [Letter to the editor]. J Rheumatol, 24(5), 1018-9.
  3. Schlesinger N, Baker DG, Schumacher HR Jr (1997). Serum urate during bouts of acute gouty arthritis. [Letter to the editor]. J Rheumatol, 24(11), 2265-6.
  4. Schlesinger N (2005). Acute gouty arthritis is seasonal: possible clues to understanding the pathogenesis of gouty arthritis. [Letter to the editor]. J Clin Rheumatol, 11(4), 240-2.
  5. Schlesinger N, Schlesinger M (2013). Previously reported prior studies of cherry juice concentrate for gout flare prophylaxis: comment on the article by Zhang et al. [Letter to the editor]. Arthritis Rheum, 65(4), 1135-6.
  6. Schlesinger N (2019). Relationship of Interleukin-1ß Blockade With Incident Gout and Serum Uric Acid Levels. [Letter to the editor]. Ann Intern Med, 170(10), 737-738.
  7. Schlesinger N, Brunetti L (2020). Treatment of Acute Gout Flares in the Emergency Department: Comment on the Article by Dalal et al. [Letter to the editor]. Arthritis Care Res (Hoboken), 72(11), 1663.
  8. Lipsky PE, Edwards NL, Fields TR, Keenan RT, Mandell BF, Schlesinger N (2020). Response to the 2020 American College of Rheumatology Guideline for the Management of Gout: Comment on the Article by FitzGerald et al. [Letter to the editor]. Arthritis Care Res (Hoboken), 72(10), 1506-1507.
  9. Schlesinger N, Dwyer J, Carson J, Brunetti (2025). Gout flare prophylaxis trials: comment on the article by Maher et al. Arthritis care & research, 77(7), 939.
  10. Schlesinger (2016). Dr. Schlesinger replies. The Journal of rheumatology, 43(8), 1617.

Abstract

  1. Schlesinger N, Baker DG, Beutler AM, Getsy J, Hoffman BI, Schumacher HR Jr (1996). Persian Gulf war myalgia syndrome [Abstract]. Arthritis Rheum, 39(9 Suppl), S47.
  2. Schlesinger N, Baker DG, Beutler AM, Getsy J, Hoffman BI, Schumacher HR Jr (1996). Acute gouty arthritis is seasonal [Abstract]. Arthritis Rheum, 39(9 Suppl), S85.
  3. Schlesinger N, Baker DG, Beutler AM, Getsy J, Hoffman BI, Schumacher HR Jr (1996). Serum uric acid during bouts of acute gouty arthritis [Abstract]. Arthritis Rheum, 39(9 Suppl), S84.
  4. Schlesinger N, Baker DG, Beutler AM, Getsy J, Hoffman BI, Schumacher HR Jr (1996). Local ice therapy during bouts of acute gouty arthritis [Abstract]. Arthritis Rheum, 39(9 Suppl), S84.
  5. Saaibi DL, Clayburne G, Schlesinger N, Schumacher HR Jr, Gowin KM (1996). Seasonal variation in serum uric acid levels [Abstract]. Arthritis Rheum, 39(9 Suppl), S85.
  6. Beutler AM, Rull M, Schlesinger N, Baker DG, Hoffman BI, Schumacher HR Jr (1996). Allopurinol may have protective effect against acute gout attacks independently from its hypouricemic action [Abstract]. Arthritis Rheum, 39(9 Suppl), S85.
  7. Schlesinger N, Farrukh K, Barrett K, Hoffman BI, Schumacher HR Jr (1997). A survey of corticosteroid use in rheumatoid arthritis [Abstract]. Arthritis Rheum, 40(9 Suppl), S194.
  8. Schlesinger N, Sieck M, Clayburne G, Schumacher HR Jr (1997). Does acute synovitis (pseudogout) occur in patients with chronic pyrophosphate arthropathy or are these separate syndromes? [Abstract]. Arthritis Rheum, 40(9 Suppl), S49.
  9. Schlesinger N, Johanson WG, Jr, Jyoti Rao, Jayanti Rao, Schumacher HR Jr (1999). A survey of current evaluation and treatment of gout [Abstract]. Arthritis Rheum, 42(9 Suppl), S536.
  10. Schlesinger N, Lardizabal A, Jayanti Rao, Jyoti Rao, Kapila R, McDonald R (1999). Tuberculosis of the spine: Experience in an inner city hospital [Abstract]. Arthritis Rheum, 42(9 Suppl), S1611.
  11. Schlesinger N (2000). Fibromyalgia in sickle cell patients: Clues to understanding the pathogenesis of fibromyalgia [Abstract]. Arthritis Rheum, 48(9 Suppl), S706.
  12. Schlesinger N, Schlesinger M, Seshan SV (2003). Seasonal Variations of Lupus Nephritis [Abstract]. Arthritis Rheum, 48(9 Suppl), S1496.
  13. Schlesinger N, Schlesinger M, Seshan SV (2003). Seasonal Variations of Lupus Nephritis [Abstract]. Journal of the American Society of Nephrology, (Supplement), #PUB554.
  14. Thiele R, Schlesinger N (2005). Ultrasonography is a reliable, non-invasive method for diagnosing gout [Abstract]. Arthritis Rheum, 52(9 Suppl), S809.
  15. Petersel D, O'Neill K, Schlesinger N (2005). Treatment of acute gout in hospitalized patients [Abstract]. Arthritis Rheum, 52(9 Suppl), S199.
  16. Borham A, El-Garf AK, Abd El-Monem, Mahmoud G, Fouad H, Schlesinger N (2005). Familial Mediterranean Fever (FMF) among Egyptians [Abstract]. Arthritis Rheum, 52(9 Suppl), S590.
  17. Schlesinger N, Norquist JM, Holmes R, Boice J, Watson DJ (2007). Validation of a patient- reported assessment of pain in acute gouty arthritis [Abstract]. Ann Rheum Dis, S0352.
  18. Schlesinger N, Ron Y, Chen CC (2007). Do cherries reduce acute gouty attacks in patients with gouty arthritis? [Abstract]. Ann Rheum Dis, S0742.
  19. Thiele R, Schlesinger N (2007). Ultrasonography shows disappearance of urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved [Abstract]. Ann Rheum Dis, S0746.
  20. Borham A, Taha R, Griffin F, Schlesinger N (2007). Post -call residents manifest a fibromyalgia-like syndrome [Abstract]. Arthritis Rheum, 56(9 Suppl), S113.
  21. Thiele R, Schlesinger N (2007). Ultrasound detects calcium pyrophosphate dehydrate crystal deposition in hyaline cartilage more readily than conventional radiography and MRI in pyrophosphate arthropathy [Abstract]. Arthritis Rheum, 56(9 Suppl), S1618.
  22. Harrison J, Faiz A, Schlesinger N (2007). Disturbed sleep in adult patients with sickle cell disease assessed by the Pittsburgh sleep quality index [Abstract]. Blood, 110(11), S.
  23. Hassett AL, Radvanski DC, Savage SV, Schlesinger N, Sigal LH (2008). Exploring the role of somatosensory amplification in fibromyalgia: pain, fatigue and functioning [Abstract]. Ann Rheum Dis, 67(Suppl 11), 254.
  24. Hassett AL, Radvanski DC, Sigal LH, Buyske S, Schlesinger N, Lehrer PM (2008). Preliminary Results from a Randomized Controlled Trial of Heart Rate Variability Biofeedback in Fibromyalgia [Abstract]. Ann Rheum Dis, 67(Suppl 11), 638.
  25. Schlesinger N, JM Norquist, J Boice, DJ Watson (2008). Serum Urate During Acute Gouty Arthritis Attacks [Abstract]. Ann Rheum Dis, 67(Suppl 11), 247.
  26. Schlesinger N, Hassett AL, Bard S, Savage SV, Das KM (2008). The prevalence and role of fibromyalgia in inflammatory bowel disease: preliminary findings [Abstract]. Ann Rheum Dis, 67(Suppl 11), 639.
  27. Norquist JM, Levine K, Schlesinger N, Boice J, Watson DJ (2008). Critical Evaluation of Recommended Outcome Assessments in Acute Gouty Arthritis [Abstract]. Ann Rheum Dis, 67(Suppl 11), 247.
  28. Thiele RG, Anandarajah AP, Tabechian D, Schlesinger N (2008). Comparing the use of ultrasonography, magnetic resonance imaging, conventional radiography high-resolution CT scanning and 3-dimensional rendering in patients with crystal proven gout [Abstract]. Ann Rheum Dis, 67(Suppl 11), 248.
  29. Schlesinger N, Norquist JM, Boice J, Watson DJ (2008). Serum Urate Levels During Acute Gout [Abstract]. Arthritis Rheum, 58(9 Suppl), S26.
  30. Thiele RG, Anandarajah AP, Tabechian D, Schlesinger N (2008). Comparing the use of ultrasonography, magnetic resonance imaging, conventional radiography high-resolution CT scanning and 3-dimensional rendering in patients with crystal proven gout [Abstract]. Arthritis Rheum, 58(9 Suppl), S805.
  31. Hassett AL, Radvanski DC, Sigal LH, Buyske S, Schlesinger N, Lehrer PM (2008). Preliminary Results from a Randomized Controlled Trial of Heart Rate Variability Biofeedback in Fibromyalgia [Abstract]. Arthritis Rheum, 58(9 Suppl), S1179.
  32. Schlesinger N, Kudipudi R, Kapila R (2009). Not everything that is infectious tenosynovitis is caused by neisseria gonorrhea [Abstract]. Ann Rheum Dis, 68(Suppl 3), S58.
  33. Schlesinger N, Savage SV, Das KM, Hassett AL (2009). The prevalence and role of fibromyalgia in inflammatory bowel disease [Abstract]. Ann Rheum Dis, 68(Suppl 3), S692.
  34. Hassett AL, Savage SV, Dihmes SE, Buyske S, Schlesinger N (2009). Positive affect as a resilience factor in fibromyalgia and other complex symptom disorders [Abstract]. Arthritis Rheum, 59(9 Suppl), S1142.
  35. Thiele RG, Schlesinger N (2009). Ultrasonography shows active inflammation in clinically unaffected joints in chronic tophaceous gout [Abstract]. Arthritis Rheum, 59(9 Suppl), S1512.
  36. So A, De Meulemeester M, Shamim T, Pikhlak A, Yücel AE, Arulmani U, Richard D, Murphy V, Sallstig P, Schlesinger N (2009). Canakinumab (ACZ885) vs. triamcinolone actonide for treatment of acute gout in patients refractory or contraindicated to NSAIDs and/or colchicine. Late breaking abstract [Abstract]. Arthritis Rheum, 60(LB4), 3660-1.
  37. Schlesinger N, De Meulemeester M, Shamim T, Pikhlak A, Yücel AE, Arulmani U, Richard D, Murphy V, Sallstig P, So A (2010). Canakinumab vs. triamcinolone acetonide for treatment of acute flares and prevention of recurrent flares in “difficult to treat” gouty arthritis [Abstract]. Journal of Clinical Rheumatology, 16(Suppl 3), S65.
  38. Schlesinger N, De Meulemeester M, Shamim T, Pikhlak A, Yucel AE, Arulmani U, Richard D, Murphy V, Sallstig P, So A (2010). Canakinumab vs. Triamcinolone Acetonide for Treatment of “difficult to treat” gouty arthritis patients. Oral presentation at the 30th World Congress of Internal Medicine, Melbourne, Australia [Abstract]. International Journal of Medicine, 40(Suppl 1), 49.
  39. Möricke R, So A, De Meulemeester M, Shamim T, Pikhlak A, Yücel E, Arulmani U, Richard D, Murphy V, Sallstig P, Schlesinger N (2010). Canakinumab (ACZ885) vs. Triamcinolone acetonide in der Behandlung von Gichtpatienten – refraktär oder kontraindiziert zur Behandlung mit NSARs und/oder Colchizin – bei akuten arthritischen Schüben und zur Prävention von wieder auftretenden Gichtattacken. Poster presented at the 117th Congress of the German Society of Internal Medicine [Abstract]. Med Klin, 105(Suppl 1), 88.
  40. So A, D Meulemeester M, Bodalia B, Shamim T, Pikhlak A, Yücel AE, Arulmani U, Richard D, Murphy V, Sallstig P, Schlesinger N (2010). Canakinumab (ACZ885) vs. triamcinolone acetonide for treatment of acute flares and prevention of recurrent flares in gouty arthritis patients refractory to or contraindicated to NSAIDS and/or colchicine. Poster presented at the British Society of Rheumatology [Abstract]. Rheumatology, 49(1), i60-1.
  41. Schlesinger N, De Meulemeester M, Shamim T, Pikhlak A, Arulmani U, Richard D, Murphy V, Sallstig P, So A (2010). Canakinumab vs. triamcinolone acetonide for treatment of acute flares and prevention of recurrent flares in “difficult to treat” gouty arthritis. Poster presented at the Pan-American League of Associations for Rheumatology Congress [Abstract]. Journal of Clinical Rheumatology, 16(3), S23.
  42. So A, De Meulemeester M, Pikhlak A, Yücel AE, Arulmani U, Richard D, Murphy V, Sallstig P, Schlesinger N (2010). Efficacy of canakinumab (ACZ885) compared to triamcinolone acetonide for treatment of acute flares and prevention of recurrent flares in gouty arthritis patients. Poster presented at SGR http://www.smw.ch/fileadmin/smw/pdf/Supplementa_2010/smw_Suppl-182.pdf [Abstract]. Swiss Med Wkly, 140(Suppl 182).
  43. Schlesinger N (2010). Prophylaxis with cherries should be considered in the treatment of gout [Abstract]. Ann Rheum Dis, 69(Suppl 3), 380.
  44. Schlesinger N, Rabinowitz R, Schlesinger M (2010). Effect of cherry juice concentrate on the secretion of interleukins by human monocytes exposed to monosodium urate crystals in vitro [Abstract]. Ann Rheum Dis, 69(Suppl 3), 379.
  45. Thiele R, Schlesinger N (2010). Ultrasound detects more erosions and tophi in gout than conventional radiography [Abstract]. Ann Rheum Dis, 69(Suppl 3), 385.
  46. So A, De Meulemeester M, Pikhlak A, Yücel AE, Arulmani U, Richard D, Stricker K, Ferreira A, Murphy V, Sallstig P, Schlesinger N (2010). Effect of canakinumab (ACZ885) and triamcinolone acetonide on the Health-Related Quality of Life (HRQoL) measures in patients with gouty arthritis [Abstract]. Ann Rheum Dis, 69(Suppl 3), 383.
  47. So A, De Meulemeester M, Pikhlak A, Yücel AE, Arulmani U, Richard D, Stricker K, Ferreira A, Murphy V, Sallstig P, Schlesinger N (2010). Canakinumab (ACZ885) vs. triamcinolone acetonide for treatment of acute flares and prevention of recurrent flares in gouty arthritis patients [Abstract]. Ann Rheum Dis, 69(Suppl 3), 291.
  48. Schlesinger N, Lin Liao HY, Whittington D, De Meulemeester M, Nasonov E, Rovensky J, Mysler E, Arulmani U, Krammer G, Murphy V, Richard D, Sallstig P, So A (2010). Efficacy of canakinumab (ACZ885) in the prevention of flares in gout patients initiating allopurinol therapy. Oral Presentation at the European League Against Rheumatism Congress, Rome, Italy [Abstract]. Ann Rheum Dis, 69(Suppl 3), S121.
  49. Thiele RG, Schlesinger N (2010). Ultrasound Detects More Erosions in Gout Than Conventional Radiography [Abstract]. Arthritis Rheum, 62(10 Suppl), S889.
  50. So A, De Meulemeester M, Pikhlak A, Yücel AE, Arulmani U, Richard D, Stricker K, Ferreira A, Murphy V, Sallstig P, Schlesinger N (2010). Rapid improvement in health-related quality of life (HRQoL) in gouty arthritis patients treated with canakinumab (ACZ885) compared to triamcinolone acetonide. Oral Presentation at the American College of Rheumatology & Association of Rheumatology Health Professionals Annual Scientific Meeting, Atlanta, GA [Abstract]. Arthritis Rheum, 62(10 Suppl), S1423.
  51. So A, De Meulemeester M, Pikhlak A, Yücel AE, Arulmani U, Richard D, Murphy V, Sallstig P, Schlesinger N (2010). Canakinumab (ACZ885) relieves Pain and Controls Inflammation rapidly In Patients with Difficult-To-Treat Gouty Arthritis: Comparison with Triamcinolone Acetonide [Abstract]. Arthritis Rheum, 62(10 Suppl), S145.
  52. Schlesinger N, Lin Liao HY, De Meulemeester M, Nasonov E, Rovensky J, Mysler E, Arulmani U, Krammer G, Balfour A, Richard D, Sallstig P, So A (2010). Efficacy of canakinumab (ACZ885), a fully human anti-Interleukin (IL)-1beta monoclonal antibody, in the prevention of flares in gout patients initiating allopurinol therapy. Oral Presentation at the ACR Plenary Session I, Discovery 2010, American College of Rheumatology/Association of Reproductive Health Professionals Annual Scientific Meeting, Atlanta, GA [Abstract]. Arthritis Rheum, 62(10 Suppl), S2087.
  53. Schlesinger N, Lin Liao HY, De Meulemeester M, Nasonov E, Rovensky J, Mysler E, Arulmani U, Krammer G, Balfour A, Richard D, Sallstig P, So A (2011). Canakinumab Provides Superior Prophylaxis Against Acute Gouty Arthritis Flares During Initiation of Allopurinol Therapy: Results of a Double-Blind, Randomised Study. Poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting, San Fransisco, CA [Abstract]. J Allergy Clin Immunol, 127(Suppl 2), AB227.
  54. Schlesinger N, Lin Liao HY, De Meulemeester M, Nasonov E, Rovensky J, Mysler E, Arulmani U, Krammer G, Balfour A, Richard D, Sallstig P, So A (2011). Canakinumab Relieves Symptoms of Acute Flares and Improves Health-Related Quality Of Life (HRQoL) in Difficult-To-Treat Gouty Arthritis Patients by Suppressing Inflammation: Results of a Randomized, Dose-Ranging Study. Poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting, San Fransisco, CA [Abstract]. J Allergy Clin Immunol, 127(Suppl 2), AB227.
  55. So A, De Meulemeester M, Pikhlak A, Yücel AE, Bodalia B, Kerrane J, Arulmani U, Richard D, Murphy V, Sallstig P, Schlesinger N (2011). Canakinumab (ACZ885) relieves pain and controls inflammation rapidly in patients with difficult-to-treat gouty arthritis: comparison with triamcinolone acetonide. Oral presentation at the British Society for Rheumatology Annual Conference [Abstract]. Rheumatology, 50(Suppl 3), iii31-4.
  56. So A, De Meulemeester M, Pikhlak A, Yücel AE, Bodalia B, Kerrane J, Arulmani U, Richard D, Stricker K, Ferreira A, Murphy V, Sallstig P, Schlesinger N (2011). Rapid improvement in health-related quality of life (HRQoL) in gouty arthritis patients treated with canakinumab (ACZ885) compared to triamcinolone acetonide. Oral presentation at the British Society for Rheumatology Annual Conference [Abstract]. Rheumatology, 50(Suppl 3), iii85-6.
  57. So A, Lin H-Y, De Meulemeester M, Nasonov E, Rovensky J, Mysler E, Arulmani U, Krammer G, Murphy V, Sallstig P, Schlesinger N (2010). Canakinumab (ACZ885) vs. colchicine in the prevention of flares in gout patients initiating allopurinol therapy. Oral presentation at the Asia-Pacific League of Associations for Rheumatology, Hong Kong [Abstract]. Int J Rheum Dis, 13(Suppl 1), 176.
  58. So A, Lin H-Y, De Meulemeester M, Nasonov E, Rovensky J, Mysler E, Arulmani U, Krammer G, Murphy V, Sallstig P, Schlesinger N (2010). Canakinumab (ACZ885) vs. colchicine in the prevention of flares in gouty arthritis patients initiating allopurinol therapy. Oral presentation at SGR 2010 [Abstract]. Swiss Med Wkly, 140(Suppl 182).
  59. Schlesinger N, Lin H-Y, De Meulemeester M, Nasonov EL, Rovensky J, Mysler E, Arulmani U, Krammer G, Balfour A, Richard D, Sallstig P, So A (2011). Efficacy of canakinumab (ACZ885), a fully human anti-interleukin (IL)-1beta monoclonal antibody, in the prevention of flares in gout patients initiating allopurinol therapy. Poster presentation at the British Society for Rheumatology [Abstract]. Rheumatology, 50(Suppl 3), iii85-6.
  60. So A, Alten R, Bardin T, Schumacher HR, Bloch M, Gimona A, Murphy A, Richard D, Schlesinger N. (2011). Canakinumab versus triamcinolone acetonide in the treatment of acute flares in gouty arthritis in patients contraindicated, intolerant or unresponsive to NSAIDs and/or colchicine [Abstract]. Ann Rheum Dis, 70(Suppl 3), 686.
  61. So A, Alten R, Bardin T, Schumacher HR, Bloch M, Gimona A, Murphy A, Richard D, Schlesinger N (2011). Canakinumab effectively reduces markers of inflammation in difficult to treat acute gouty arthritis: results from two controlled trials comparing canakinumab with triamcinolone acetonide [Abstract]. Ann Rheum Dis, 70(Suppl 3), 686.
  62. Schlesinger N, Alten R, Schumacher HR, Bardin T, Bloch M, Shpilsky A, Gimona A, Kiechle T, Krammer G, So A (2011). Long-term safety and efficacy of canakinumab (ACZ885) in the prevention of flares in gouty arthritis patients [Abstract]. Ann Rheum Dis, 70(Suppl 3), 181.
  63. Schlesinger N, Alten R, Schumacher HR, Bardin T, Bloch M, Shpilsky A, Gimona A, Kiechle T, Krammer G, So A (2011). Efficacy of canakinumab versus triamcinolone acetonide in acute gouty arthritis patients: results of the β-relieved ii study (response in acute flare and in prevention of episodes of re-flare in gout). Oral presentation at the EULAR, Annual European Congress of Rheumatology, London, England, United Kingdom [Abstract]. Ann Rheum Dis, 70(Suppl 3), 186.
  64. Schlesinger N, Alten R, Schumacher HR, Bardin T, Bloch M, Shpilsky A, Gimona A, Kiechle T, Krammer G, So A (2011). Efficacy of canakinumab vs triamcinolone acetonide in preventing recurrent flares in acute gouty arthritis patients contraindicated, intolerant or unresponsive to NSAIDs and/or colchicine: results from two pivotal studies [Abstract]. Ann Rheum Dis, 70(Suppl 3), 103.
  65. So A, Alten R, Bardin T, Bloch M, Schumacher HR, Rolfe A, Murphy V, Sallstig P, Richard D, Gimona A. Schlesinger N (2011). A controlled trial of canakinumab vs triamcinolone acetonide in acute gouty arthritis patients: results of the β-relieved study (response in acute flare and in prevention of episodes of re-flare in gout) [Abstract]. Ann Rheum Dis, 70(Suppl 3), 104.
  66. Bardin T, Schlesinger N, Alten R, Bloch M, Schumacher HR, Gimona A, Krammer G, Tao A, Stricker K , So A (2011). Surrogate markers of comorbidities: impact of canakinumab versus triamcinolone acetonide in acute gouty arthritis patients [Abstract]. Ann Rheum Dis, 70(Suppl 3), 182.
  67. Bardin T, Schlesinger N, Alten R, Bloch M, Schumacher HR, Gimona A, Krammer G, Tao A, Stricker K , So A (2011). Baseline epidemiology characteristics of comorbidities in gouty arthritis patients frequently flaring: results from two pivotal studies [Abstract]. Ann Rheum Dis, 70(Suppl 3), 697.
  68. Dundeva-Baleva P, Abdel-Megid A, Borham A, Schlesinger N (2011). Trochanteric Bursitis: Is there Ultrasonographic Evidence to Suggest Inflammation? [Abstract]. Arthritis Rheum, 63(10 Suppl), S1898.
  69. Sunkureddi P, Bardin T, Alten R, Schlesinger N, Bloch M, Kiechle T, Krammer G, Shpilsky A, So A (2011). Effect of IL-1β Inhibition with Canakinumab Compared to Triamcinolone Acetonide on Pain Intensity and New Flares in Gouty Arthritis Patients with Chronic Kidney Disease Stage 2-5 [Abstract]. Arthritis Rheum, 63(10 Suppl), S1020.
  70. So A, Alten R, Schumacher HR, Bardin T, Bloch M, Richard D, Karpov A, Kiechle T, Schlesinger N (2011). Inflammation Suppression over 24 Weeks in Patients with Gouty Arthritis: Results from two Phase-III Core and Extension Studies Comparing Canakinumab with Triamcinolone Acetonide [Abstract]. Arthritis Rheum, 63(10 Suppl), S1019.
  71. Brown JP, So A, Dikranian A, Alten R, Bardin T, Schumacher HR, Gimona A, Krammer G, Karpov A, Schlesinger N (2011). Long-term efficacy and safety of canakinumab versus triamcinolone acetonide in acute gouty arthritis patients [Abstract]. Arthritis Rheum, 63(10 Suppl), S1016.
  72. Alten R, So A, Kivitz A , Bardin T, Bloch M, Gimona A, Widmer A, Krammer G, Schlesinger N, Schumacher HR (2011). Efficacy of Canakinumab vs Triamcinolone Acetonide Re-Treatment in Gouty Arthritis Patients with Limited Treatment Options: 24- Week Results from β-RELIEVED and β-RELIEVED-II Studies [Abstract]. Arthritis Rheum, 63(10 Suppl), S1029.
  73. Schlesinger N, Brown JP, Bardin T, Kiechle T, Shpilsky A, Alten R, So A (2011). Comparison of Pain Intensity, Incidence of New Flares, Safety and Tolerability of Canakinumab vs Triamcinolone Acetonide in Gouty Arthritis Patients with Cardiovascular Diseases or with Cardiovascular Risk Factors [Abstract]. Arthritis Rheum, 63(10 Suppl), S1028.
  74. Sunkureddi P, Schlesinger N, Kiechle T, Shpilsky A, So A (2012). Effect of serum urate level on prevention of flare in acute gouty arthritis patients with canakinumab [Abstract]. Ann Rheum Dis, 71(Suppl 3), 699.
  75. Sunkureddi P, Bardin T, Alten R, Schlesinger N, Bloch M, T Kiechle T, Krammer G, Shpilsky A, So A (2012). Efficacy and safety of canakinumab in gouty arthritis patients with chronic kidney disease stage ≥3 [Abstract]. Ann Rheum Dis, 71(Suppl 3), 447.
  76. Schlesinger N, Dundeva-Baleva P, Abdel-Megid A, Borham A (2012). Trochanteric Bursitis: Is there Ultrasonographic Evidence to Suggest Inflammation? [Abstract]. Ann Rheum Dis, 71(Suppl 3), 275.
  77. Schlesinger N, Sunkureddi P, Alten R, Bardin T, Shpilsky A, Kiechle T, So A (2012). The spread of tophaceous disease strongly predicts time to new flare in gouty arthritis [Abstract]. Ann Rheum Dis, 71(Suppl 3), 699.
  78. Schlesinger N, Alten R, Bardin T, Bloch M, Shpilsky A, Krammer G, Kiechle T, So A (2012). Effect of canakinumab vs triamcinolone acetonide for treatment of gouty arthritis in patients who are unable to use NSAIDs and colchicine or with severe gouty arthritis. Poster tour EULAR, Annual European Congress of Rheumatology, Madrid, Spain [Abstract]. Ann Rheum Dis, 71(Suppl 3), 439.
  79. So A, Bardin T, Bloch M, Shpilsky A, Kiechle T, Schlesinger N (2012). Early response to treatment is a surrogate marker of flare recurrence in acute gouty arthritis [Abstract]. Ann Rheum Dis, 71(Suppl 3), 441.
  80. Bardin T, Alten R, Schlesinger N, Shpilsky A, Kiechle T, So A (2012). Tophi spread, acute joints and flare frequency predict reflare in gouty arthritis: a spatio-temporal mode [Abstract]. Ann Rheum Dis, 71(Suppl 3), 450.
  81. Alten R, Bloch M, Bardin T, So A, Shpilsky A, Nebesky JM, Kiechle, Schlesinger N (2012). Efficacy and safety of canakinumab vs triamcinolone acetonide in persistent or elderly gouty arthritis patients [Abstract]. Ann Rheum Dis, 71(Suppl 3), 700.
  82. So A, Alten R, Schumacher HR, Bloch M, Bardin T, John MR, Krammer G, Nebesky JM, Tao A, Schlesinger N (2012). Long-term safety and efficacy of canakinumab in patients with gouty arthritis [Abstract]. Arthritis Rheum, 64(10 Suppl), S144.
  83. Bardin T, So A, Alten R, Bloch M, John MR, Krammer G, Nebesky JM, Tao A, Schlesinger N (2012). Efficacy and Safety of Canakinumab vs Triamcinolone Acetonide in Patients with Gouty Arthritis Unable to Use Non-steroidal Anti-Inflammatory Drugs and Colchicine, and on Stable ULT or Unable to Use ULT [Abstract]. Arthritis Rheum, 64(10 Suppl), S1911.
  84. Schlesinger N, Radvanski D, Young TC , Eisenstein R, Moore DF (2013). Diagnosis and treatment of acute gouty arthritis at a university hospital Emergency Department [Abstract]. Ann Rheum Dis, 72(Suppl 3), 381.
  85. Schlesinger N, Radvanski D, Tomanovich P (2013). Association of gouty arthritis severity with patients’ mental and physical health-related quality of life, work productivity and medical resource utilization [Abstract]. Ann Rheum Dis, 72(Suppl 3), 353.
  86. Harrold LR, Etzel C, Greenberg J, Pillinger M, Saag K, Schlesinger N, Terkeltaub R, Cox V, Kremer J (2013). Sex Differences in Gout Evaluation and Management [Abstract]. Arthritis Rheum, 65(10 Suppl), S506.
  87. Schlesinger N, Young TC, Radvanski D, Moore DF, Eisenstein R (2013). Treatment of acute gout in the emergency department evaluated according to the 2012 American College of Rheumatology guidelines. Poster presented at the American College of Rheumatology/Association of Reproductive Health Professionals Annual Scientific Meeting, San Diego, CA [Abstract]. Arthritis Rheum, 65(10 Suppl), S848.
  88. Hsu VM, Bramwit M, Schlesinger N (2014). Dual Energy Computed Tomography for the evaluation of calcinosis in systemic sclerosis [Abstract]. Ann Rheum Dis, 73(Suppl 2), 571.
  89. Alten R, Schlesinger N, So A, Schumacher HR,Bloch M, Machein U, Richard D, Lheritier K, Bardin T (2014). Long-term safety and efficacy of canakinumab vs. triamcinolone acetonide in patients with frequent acute gouty arthritis attacks who are contraindicated, intolerant or unresponsive to NSAIDs and/or colchicine [Abstract]. Ann Rheum Dis, 73(Suppl 2), 785.
  90. Harrold LR, Etzel C, Gibofsky A, Kremer J, Pillinger M, Saag KG, Schlesinger N, Terkeltaub R, Cox V, Greenberg J (2014). Sex differences in gout characteristics: tailoring care for women and men. Oral Presentation at the EULAR, Annual European Congress of Rheumatology, Paris, France [Abstract]. Ann Rheum Dis, 73(Suppl 2), 112.
  91. Schlesinger N, Radvanski D, Kostis JB (2014). Erectile dysfunction in gout patients. Oral presentation at the EULAR, Annual European Congress of Rheumatology, Paris, France [Abstract]. Ann Rheum Dis, 73(Suppl 2), 111-2.
  92. Schlesinger N, Etzel C, Greenberg J, Kremer J, Harrold L (2014). Gout flare prophylaxis evaluated according to the 2012 American College of Rheumatology (ACR) guidelines: analysis from the CORRONA Gout Registry. Poster presented at the 4th Eastern Forum of Gout, Beijing, China [Abstract]. Ann Rheum Dis, 73(Suppl 2), 782.
  93. Schlesinger N, Radvanski D, Kostis JB (2014). All Men with Gout Should Be Screened For Erectile Dysfunction [Abstract]. Arthritis Rheum, 66(10 Suppl), S160.
  94. Hsu VM, Bramwit M, Schlesinger N (2014). Dual Energy Computed Tomography for the evaluation of calcinosis in systemic sclerosis [Abstract]. Arthritis Rheum, 66(10 Suppl), S159.
  95. Schlesinger N, Alten R, Schumacher HR, Bloch M, Lheritier K, Richard D, Bardin T, Stancati A, So A (2014). Canakinumab in Frequent Flaring Gouty Arthritis Patients, Contraindicated, Intolerant or Unresponsive to NSAIDs and/or Colchicine: Safety and Efficacy Results from Long Term Follow-up [Abstract]. Arthritis Rheum, 66(10 Suppl), S1686.
  96. Alten R, Bardin T, Schumacher HR, Bloch M, Lheritier K, , Machein U, Junge G, So A, Schlesinger N (2015). Safety and Efficacy of Canakinumab in Frequently Flaring Gouty Arthritis Patients who are Contraindicated, Intolerant or Unresponsive to Non-Steroidal Antiinflammatory drugs and/or Colchicine: Results from 3 years follow-up [Abstract]. Ann Rheum Dis, 74(Suppl 2), 544.
  97. Vargas dos Santos AB, da Rocha Castelar Pinheiro G, Freire Coutinho ES, Schlesinger N (2015). A Survey Of Gout Treatment By Brazilian Rheumatologists Evaluated According To The 2012 ACR Guidelines [Abstract]. Ann Rheum Dis, 74(Suppl 2), 1206.
  98. Biernat-Kaluza E, Schlesinger N (2015). Lemon juice reduces serum uric acid level via alkalization of urine in gouty and hyperuremic patients-a pilot study [Abstract]. Ann Rheum Dis, 74(Suppl 2), 774.
  99. Schlesinger N, Bardin T, Bloch M, Lheritier K, Machein U, Junge G, So A, Alten R (2015). 3-Year Follow-up Study of Canakinumab in Frequently Flaring Gouty Arthritis Patients, Contraindicated, Intolerant, or Unresponsive to Nonsteroidal Anti-inflammatory Drugs and/or Colchicine [Abstract]. Arthritis Rheum, 67(10 Suppl), 2344.
  100. Hsu VM, Emge T, Schlesinger N (2015). X-ray diffraction of spontaneously draining calcinosis in patients with scleroderma [Abstract]. Arthritis Rheum, 67(10 Suppl), 2969.
  101. Schlesinger N, Khanna P, Yeo A, Lipsky P (2017). Evidence-Based Development of Criteria for Complete Response in Patients with Chronic Refractory Gout. Poster presentation at the EULAR, Annual European Congress of Rheumatology, Madrid, Spain. 69(10 Suppl),
  102. Li X, Wei Q, Schlesinger N, G (2017). Investigation on Allele Frequency of Rs3117583 and Rs9263726 in Patients with Hyperuricemia or Gout. 69(10 Suppl),
  103. Young NA, Jablonski K, Sharma J, Thomas E, Snoad B, Hampton J, Jarjour W, Schlesinger (2017). Low and Moderate Intensity Exercise Suppresses Inflammatory Responses in an Acute Mouse Model of Gout and Suggests Therapeutic Efficacy. 69(10 Suppl),
  104. Jablonski K, Sandoval B, Harb P, Kalyanasundaram A, Hampton JM, Jarjour WN, Schlesinger N, Young N (2018). Moderate physical activity downregulates TLR2 expression on circulating neutrophils and leads to reduced IL-1β locally in an acute mouse model of gout. Oral presentation at the EULAR, Annual European Congress of Rheumatology, Amsterdam, Netherlands. 77(Suppl), 204.
  105. Young NA, Jablonski K, Sandoval B, Kalyanasundaram A, Harb P, Hampton JM, Jarjour WN, Schlesinger (2018). Daily exercise suppresses acute pro-inflammatory cytokine expression systemically and IL-1β locally in a murine model of gout. 77(Suppl), 1235.
  106. Aamar S, Kerpel A, Rabinowitz R, Levy P, Zelig O, Schlesinger N, Schlesinger (2018). Cell surface antigens and Intracytoplasmic cytokines in CD20 bright and low lymphocyte subpopulations in rheumatoid arthritis patients. Oral presentation at the EULAR, Annual European Congress of Rheumatology, Amsterdam, Netherlands. 77(Suppl), 268.
  107. Elsaid MI, Rustgi VK, Schlesinger (2018). The Relationship between Metabolic Syndrome Severity and the Risk of Mortality in Gout Patients: A population Based Study. 70(10 Suppl),
  108. Mandell BF, Schlesinger N, Edwards NL, Yeo A, Lipsky (2018). Influence of renal function on the velocity of tophus resolution and achievement of disease remission in patients with chronic refractory gout treated with pegloticase. 70(10 Suppl),
  109. Jablonski K, Young NA, Sandoval B, Harb P, Scharwz E Henry C, Kalyanasundaram A, Okafor I, Jarjour WN, Schlesinger (2018). Physical Activity at Lower Intensities Reduces Localized IL-1b in Murine Model of Gout by Systemically Down-Regulating TLR2 Expression on Circulating Neutrophils and Suppressing CXCL1 Expression. 70(10 Suppl),
  110. Young NA, Jablonski K, Sandoval B, Harb P, Scharwz E Henry C, Arbaji H, Okafor I, Jarjour WN, Schlesinger (2018). Oral Cherry Juice Concentrate Inhibits Localized NFκB activity and Histopathological Infiltrates in a Murine Model of Acute Gout. 70(10 Suppl),
  111. Schlesinger N, Edwards NL, Yeo A, Lipsky (2019). Development of a Multivariable Improvement Measure for Gout. Oral presentation. 78(Suppl 2),
  112. Schlesinger N, Elsaid MI, Rustgi V (2019). The Relationship between Metabolic Syndrome Severity and the Risk of Mortality in Gout Patients: A population Based Study. 78(Suppl 2),
  113. Schlesinger N, Alikhan M, Doty (2019). Is the Sense of Smell Impaired in Gout Patients?. 78(Suppl 2),
  114. Edwards L, Schlesinger N, Clark S, Arndt T, Lipsky (2019). Management of Advanced Gout: a Claims-Based Analysis from the United States. 78(Suppl 2),
  115. Sidor M, Zuckerman R, Schlesinger N, Sussman R, Sabahath H, Hsu (2019). Ultrasound Measurement of the Nail Bed Matrix Thickness as a Useful Marker for Scleroderma-Related Interstitial Lung Disease. Poster presentation at the 6th Systemic Sclerosis World Congress (virtual). 71(10 Suppl),
  116. Hsu V, Schlesinger N, Li Q, Varga (2019). Reduced Circulating Levels of Inorganic Pyrophosphate Are Associated with Ectopic Calcification in Scleroderma Spectrum Disorders. Poster presentation at the 6th Systemic Sclerosis World Congress (virtual). 71(10 Suppl),
  117. Edwards N, Schlesinger N, Clark S, Paige J, Arndt T, Lipsky (2019). Gout Management in the Medical Community: A Claims-Based Analysis. 71(10 Suppl),
  118. Schlesinger N, Edwards N, Clark S, Lipsky (2019). Rheumatologist Care Is Associated with Fewer Emergency Room Visits by Persons with Gout. 71(10 Suppl),
  119. Schlesinger N, Edwards N, Yeo A, Lipsky (2019). Development of a Multivariable Improvement Measure for Gout. 71(10 Suppl),
  120. Schlesinger N, Yeo A, Lipsky (2019). Improvement in Hepatic Fibrosis Estimated by Fibrosis-4 (FIB-4) Index in Subjects with Chronic Refractory Gout Treated with Pegloticase. 71(10 Suppl),
  121. Schlesinger N, Jablonski K, Harb P, Henry C, Schwarz E, Okafor I, Jarjour W, Young (2019). Increased Physical Activity in Gout Patients Correlates with Better Prognosis, Decreased Pain, and Suppressed C-Reactive Protein Levels. 71(10 Suppl),
  122. Schlesinger N, Edwards N, Clark S, Lipsky (2020). Rheumatologist Care Is Associated with Fewer Emergency Room Visits by Persons with Gout. 79(Suppl 1), 1873.
  123. Schlesinger N, Yeo A, Lipsky (2020). Improvement in Hepatic Fibrosis Estimated by Fibrosis-4 (FIB-4) Index in Subjects with Chronic Refractory Gout Treated with Pegloticase. 79(Suppl 1), 450.
  124. Brunetti L, Vekaria J, Lipsky P, Schlesinger (2020). Readmission Risk and Quality of Care in Patients Presenting to the Emergency Department with Gout Flares. Poster presentation at the Asia-Pacific League of Associations For Rheumatology Congress, Kyoto, Japan. 79(Suppl 1), 442.
  125. Sherman Y, Lipsky P, Bramwit M, Schlesinger (2020). Dual-Energy Computed Tomography in Gout Patients: Is it Useful in General Practice?. 79(Suppl 1), 1763.
  126. Schlesinger N, Jablonski K, Schwarz E, Young (2020). Physical Activity Decreases Pain and Inflammation in Gout Patients. Poster presentation at the Asia-Pacific League of Associations for Rheumatology, Kyoto, Japan. 79(Suppl 1), 1762.
  127. Brunetti L, Vekaria J, Lipsky P, Schlesinger (2020). Readmission Risk and Quality of Care in Patients Presenting to the Emergency Department with Gout Flares. 72(10 Suppl),
  128. Brunetti L, Diawara O, Tsai A, Firestein B, Nahass R, Poiani G, Schlesinger (2020). Colchicine to Weather the Storm in Hospitalized Patients with COVID-19. 72(10 Suppl),
  129. Brunetti L, Wang L, Wassef A, Brinker A, Buckley B, Lipsky P, Kong A, Schlesinger (2021). Pharmacokinetics and Pharmacodynamics of Anthocyanins After Oral Administration of Oral Tart Cherry Juice Concentrate to Gout Patients. 73(10 Suppl),
  130. Schlesinger N, Sumpter N, Dalbeth N, Stamp L, Merriman (2021). Is There a Difference in Self-reported Flare Frequency Between Men and Women?. 73(10 Suppl),

Other

  1. Schlesinger N (2002). Readers want to know. Should one ice a gouty knee? (16, p. 16).

Video/Film/CD/Web/Podcast

  1. Wick G, Anaya JM, Andrarde, Schlesinger N, Touinou P, et al (2019). Allowing an open discussion of the side effects of vaccines [e-letter] [Web], Science. Available: https://science.sciencemag.org/content/366/6466/675/tab-e-letters.
  2. Schlesinger N (2009). Managing Gout - From Acute Relief to Long-term Control [Web], Medscape CME. Available: http://cme.medscape.com/viewarticle/701583.
  3. Schlesinger N (2012). Gout Diagnosis: 4 Common Misconceptions [Web], www.consultantlive.com: Consultant Live. Available: http://www.consultantlive.com/musculoskeletal-disorders/display/article/10162/2099778.
  4. Schlesinger N (2018). Gout linked to increased risk for erectile dysfunction [Web], Healio News. Available: https://www.healio.com/rheumatology/gout/news/online/ %7B3f32ad1e-b43a-4cd6-b5f1-e8423a85ec0c%7D/gout-linked-to-increased-risk-for- erectile-dysfunction.